skip to main content

S. 2157: Drug-Price Transparency in Communications Act

A bill to require drug manufacturers to disclose the prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug.

The bill’s titles are written by its sponsor.

Richard Durbin

Sponsor. Senior Senator for Illinois. Democrat.

Read Text »
Last Updated: Nov 16, 2017
Length: 8 pages
Introduced:

Nov 16, 2017

Status:

Introduced on Nov 16, 2017

This bill is in the first stage of the legislative process. It was introduced into Congress on November 16, 2017. It will typically be considered by committee next before it is possibly sent on to the House or Senate as a whole.

Prognosis:

1% chance of being enacted according to Skopos Labs (details)

History

Nov 16, 2017
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

Pending
 
Ordered Reported

Pending
 
Passed Senate (House next)

Pending
 
Passed House

Pending
 
Signed by the President

S. 2157 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“S. 2157 — 115th Congress: Drug-Price Transparency in Communications Act.” www.GovTrack.us. 2017. December 17, 2017 <https://www.govtrack.us/congress/bills/115/s2157>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.